Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
02:31pm, Thursday, 13'th Jun 2024
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of m
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
10:00am, Tuesday, 11'th Jun 2024
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify t
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
12:36pm, Thursday, 06'th Jun 2024
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
01:15pm, Thursday, 23'rd May 2024
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Esperion to Participate in Upcoming June Investor Conferences
09:00am, Thursday, 23'rd May 2024
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, wh
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
06:00am, Monday, 20'th May 2024
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Ja
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
05:43am, Monday, 20'th May 2024
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
08:00am, Tuesday, 14'th May 2024
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for b
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:00pm, Friday, 10'th May 2024
ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
01:20pm, Wednesday, 08'th May 2024
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
08:22am, Tuesday, 07'th May 2024
Esperion Therapeutics (NASDAQ: ESPR ) stock is up on Tuesday after the pharmaceutical company released its earnings report for the first quarter of 2024. The good news from this earnings report inclu
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
08:16am, Tuesday, 07'th May 2024
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago
Esperion Reports First Quarter 2024 Financial Results
06:00am, Tuesday, 07'th May 2024
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Gre
Esperion to Participate in Upcoming May Investor Conferences
08:00am, Monday, 29'th Apr 2024
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May,
